Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D'Incalci M. Belgiovine C, et al. Among authors: galmarini cm. Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6. Br J Cancer. 2017. PMID: 28683469 Free PMC article.
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, Paz-Ares L. Farago AF, et al. Among authors: galmarini cm. Future Oncol. 2019 Jan;15(3):231-239. doi: 10.2217/fon-2018-0597. Epub 2018 Oct 26. Future Oncol. 2019. PMID: 30362375 Free PMC article. Clinical Trial.
MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors.
Avilés P, Domínguez JM, Guillén MJ, Muñoz-Alonso MJ, Mateo C, Rodriguez-Acebes R, Molina-Guijarro JM, Francesch A, Martínez-Leal JF, Munt S, Galmarini CM, Cuevas C. Avilés P, et al. Among authors: galmarini cm. Mol Cancer Ther. 2018 Apr;17(4):786-794. doi: 10.1158/1535-7163.MCT-17-0795. Epub 2018 Feb 13. Mol Cancer Ther. 2018. PMID: 29440297
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
Céspedes MV, Guillén MJ, López-Casas PP, Sarno F, Gallardo A, Álamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Avilés P, Mangues R. Céspedes MV, et al. Among authors: galmarini cm. Dis Model Mech. 2016 Dec 1;9(12):1461-1471. doi: 10.1242/dmm.026369. Epub 2016 Oct 20. Dis Model Mech. 2016. PMID: 27780828 Free PMC article.
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M. Romano M, et al. Among authors: galmarini cm. Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10. Br J Cancer. 2017. PMID: 28072764 Free PMC article.
129 results